LataMed AI Corp. (OTC: LMED) provided shareholders with an update on its previously announced 5-for-1 forward stock split and related mandatory share exchange process, revealing that all requested information has been submitted to FINRA as of July 7, 2026. Management anticipates the corporate action may become effective within approximately the next week, pending FINRA’s review and final processing. The company will issue a further update once the official effective date is established.
The forward stock split will be implemented alongside the assignment of a new CUSIP number, 21116R404, which will replace the current CUSIP upon effectiveness. This change is designed to facilitate the mandatory share exchange process and support the company’s updated capital structure.
In its announcement, LataMed AI provided guidance on how the exchange process will be administered for different types of shareholders. For shareholders holding shares through a brokerage account, no action is required, as brokerage firms and custodians are expected to process the exchange automatically through normal settlement procedures. Similarly, registered book-entry shareholders—those holding shares directly with the company’s transfer agent—generally do not need to submit documentation, as the transfer agent will update accounts to reflect the post-split share balance and new CUSIP.
Shareholders who hold physical stock certificates registered in their own names are not required to immediately surrender their certificates. However, because the forward stock split is tied to a mandatory CUSIP exchange, existing certificates will represent the pre-exchange security. When a shareholder later submits a certificate for transfer, sale, or exchange, it will be processed under the mandatory exchange procedures. The transfer agent will then issue the appropriate number of post-split shares under the new CUSIP. Additional instructions regarding certificate submission, documentation, and processing timelines will be provided by the transfer agent as the process moves forward.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., emphasized the importance of clear communication: “We want to ensure that our shareholders clearly understand how the forward stock split and mandatory exchange process will be implemented. While the vast majority of shareholders are expected to have their shares updated automatically, we believe it is important to provide clear guidance for shareholders holding physical stock certificates.”
Looking ahead, management intends to focus on advancing the company’s telemedicine platform and pursuing licensing and commercialization opportunities for its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms. Dr. Levy noted that these initiatives are key components of the company’s long-term strategy to build an integrated digital healthcare ecosystem in Latin America.
The forward stock split is seen as supporting the company’s corporate development and strategic initiatives. Shareholders with questions are encouraged to contact their brokerage firm or the company’s transfer agent once detailed exchange instructions are available. Additional updates on the effective date and implementation timeline will be provided as the corporate action progresses. For more information, visit https://latamed.ai or review the company’s filings with the SEC at www.sec.gov.
